Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Krystal Biotech, Inc. Director's Dealing 2017

Sep 20, 2017

31006_dirs_2017-09-19_45ccbad7-f498-423d-9901-dc469707626f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Krystal Biotech, Inc. (KRYS)
CIK: 0001711279
Period of Report: 2017-09-19

Reporting Person: NORBY R DOUGLAS (Director)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $11.07 2026-11-29 Common Stock (18949) Direct

Footnotes

F1: The options were awarded on November 30, 2016 and vest ratably over a four-year period.